SkylineDx to Present New Data on MMprofiler™ at EHA
News Jun 04, 2016
SkylineDx announced the presentation of four posters that reconfirm the prognostic value of MMprofiler™ with SKY92, the only gene-based signature proven superior to the biomarkers currently used for risk-stratifying newly-diagnosed and relapsed multiple myeloma patients.1 Of the four posters, three will be presented Friday, June 10, 2016, at the European Hematology Association (EHA) 21st Annual Congress in Copenhagen, Denmark. The fourth will be presented as an E-poster. Additionally, SkylineDx will host a “Meet the Experts” event in booth #C4.328 on June 10, from 2:30 – 3:30 p.m. (CEST).
Each of the four new abstracts utilized MMprofiler and its novel gene signature, SKY92, to determine the prognostic validity in both the clinical and analytical setting in identifying high risk or standard risk stratification in patients with multiple myeloma. Results show that the SKY92 signature, a key component of MMprofiler, is a powerful and robust prognostic marker, not only for overall survival, but also for progression free survival in younger, elderly, newly diagnosed, and relapsed patients with multiple myeloma across various treatments. Moreover, it can be used reliably as a predictor for survival to optimize follow-up and treatment strategies in an early stage.
“We are pleased to showcase MMprofiler and its reliability in determining risk stratification to optimize treatment in patients with multiple myeloma through these four posters,” said Dharminder S. Chahal, Chief Executive Officer of SkylineDx. “We are confident that these additional studies will help inform patients and physicians with clinically actionable information that will guide and speed up the therapeutic decision-making process, no matter what stage of the disease the patient is experiencing.”
MMprofiler with SKY92 is a gene-based risk identification signature that determines the level of risk for patients with multiple myeloma by classifying them into a “high” or “standard” risk group. MMprofiler assesses risk by measuring the activity of 92 genes (the SKY92 gene signature) that are directly or indirectly related to the disease. Patients with a “high” risk classification have a poor prognosis as compared to patients with a standard risk profile, regardless of treatment. The performance of the SKY92 gene signature to risk stratify these patients exceeds that of standard clinical parameters that include FISH, and earlier gene expression signatures utilized in myeloma.
“With the information that MMprofiler provides, physicians are now able to make better informed decisions,” said Antonio Palumbo, M.D., Chief of Myeloma Unit, Department of Oncology, University of Torino, Italy. “The power to classify a patient’s risk level using MMprofiler enables the physician to potentially tailor a more precise and beneficial treatment for their multiple myeloma patient, thus potentially avoiding ineffective, costly, or potentially harmful treatments.”
Researchers have created a portable and fast-acting test that can distinguish Ebola infections from other fever-causing infectious diseases such as Lassa fever and malaria in around 30 minutes. Although further testing is required, this could be useful during febrile disease outbreaks.READ MORE